Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tedizolid (Primary) ; Linezolid
  • Indications Gram-positive infections; Ventilator associated pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL
  • Sponsors Cubist Pharmaceuticals; Trius Therapeutics

    • Most Recent Events

    • 22 Sep 2023 Results applying Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in VITAL and other study, published in the Clinical Infectious Diseases
    • 10 Dec 2022 This trial has been discontinued in Italy according to European Clinical Trials Database record.
    • 15 Mar 2021 Results assessing efficacy and safety of tedizolid for treatment of gram-positive ventilated gram-positive nosocomial pneumonia, published in the Clinical Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top